3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
NEW YORK, December 6, 2019 /PRNewswire/ — 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted…
Read More
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
NEW YORK, Nov. 19, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational…
Read More
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
NEW YORK, April 2, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and…
Read More